We are live on ! Find out more
RhumbLine Advisers

RhumbLine Advisers Portfolio holdings

AUM $117B
1-Year Est. Return 29.66%
This Fund
S&P 500
This Quarter Est. Return
+3.24%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.91%
AUM
$33.7B
AUM Growth
+$1.52B
Cap. Flow
+$861M
Cap. Flow %
2.55%
Top 10 Hldgs %
14.52%
Holding
3,141
New
144
Increased
1,491
Reduced
1,301
Closed
155

Sector Composition

Rank Sector Weight
1 Healthcare 14.29%
2 Financials 14.18%
3 Technology 13.8%
4 Industrials 10.4%
5 Consumer Discretionary 9.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CAMP
2026
DELISTED
CalAmp Corp.
CAMP
$652K ﹤0.01%
1,914
+56
+3% +$19.7K
SAN icon
2027
Banco Santander
SAN
$202B
$651K ﹤0.01%
173,336
NRE
2028
DELISTED
NorthStar Realty Europe Corp.
NRE
$648K ﹤0.01%
70,033
+30,112
+75% +$338K
FBP icon
2029
First Bancorp
FBP
$4.42B
$647K ﹤0.01%
162,994
-34,080
-17% -$128K
NGG icon
2030
National Grid
NGG
$80.6B
$646K ﹤0.01%
9,009
+130
+1% +$8.99K
EBF icon
2031
Ennis
EBF
$552M
$645K ﹤0.01%
33,647
-7,380
-18% -$140K
MFRM
2032
DELISTED
MATTRESS FIRM HLDG CORP COM STK (DE)
MFRM
$645K ﹤0.01%
19,220
-1,855
-9% -$68K
FWONA icon
2033
Liberty Media Series A
FWONA
$22.6B
$644K ﹤0.01%
35,168
-105,714
-75% -$2.06M
ARRY
2034
DELISTED
Array Biopharma Inc
ARRY
$643K ﹤0.01%
180,610
+18,403
+11% +$60K
MTUS icon
2035
Metallus
MTUS
$836M
$642K ﹤0.01%
66,726
-11,517
-15% -$120K
KERX
2036
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$642K ﹤0.01%
97,024
-10,287
-10% -$57.5K
HFWA icon
2037
Heritage Financial
HFWA
$1.22B
$640K ﹤0.01%
36,424
-8,684
-19% -$154K
INO icon
2038
Inovio Pharmaceuticals
INO
$54.3M
$640K ﹤0.01%
5,769
-232
-4% -$28.2K
AVTA
2039
DELISTED
Avantax, Inc. Common Stock
AVTA
$640K ﹤0.01%
61,796
-9,516
-13% -$74.8K
CERS icon
2040
Cerus
CERS
$435M
$639K ﹤0.01%
102,344
+999
+1% +$5.95K
CSII
2041
DELISTED
Cardiovascular Systems, Inc.
CSII
$639K ﹤0.01%
34,788
+3,185
+10% +$49.8K
SXC icon
2042
SunCoke Energy
SXC
$717M
$638K ﹤0.01%
109,632
+13,994
+15% +$88.3K
SPPI
2043
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$638K ﹤0.01%
97,129
-15,556
-14% -$110K
HRTX icon
2044
Heron Therapeutics
HRTX
$92.9M
$635K ﹤0.01%
35,201
+6,067
+21% +$118K
RUTH
2045
DELISTED
Ruth's Hospitality Group, Inc.
RUTH
$635K ﹤0.01%
39,806
-6,394
-14% -$109K
CACQ
2046
DELISTED
Caesars Acquisition Company
CACQ
$634K ﹤0.01%
56,485
-14,577
-21% -$129K
NAV
2047
DELISTED
Navistar International
NAV
$632K ﹤0.01%
54,035
-15,883
-23% -$197K
FTD
2048
DELISTED
FTD Companies, Inc. Common Stock
FTD
$632K ﹤0.01%
25,319
-5,900
-19% -$156K
SGYP
2049
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$632K ﹤0.01%
166,429
+69,265
+71% +$235K
FBC
2050
DELISTED
Flagstar Bancorp, Inc. New
FBC
$631K ﹤0.01%
25,832
-5,860
-18% -$136K

Similar funds

RhumbLine Advisers's Q2 2016 Portfolio in Review

As of Q2 2016, RhumbLine Advisers held 3,141 positions worth $33.7B, up 4.7% from $32.2B the previous quarter. Its ten largest holdings account for 15% of the portfolio.

RhumbLine Advisers's Q2 2016 filing shows 144 new, 1,491 increased, 1,301 reduced and 155 closed positions. Its largest new stake was S&P Global: 401,386 shares worth $43.1M. The largest sale was TIME WARNER CABLE INC NEW COM STK, an estimated $86.8M.

By sector, the portfolio is most concentrated in Healthcare at 14% of assets, up from 14% a quarter earlier, followed by Financials and Technology.

  • RhumbLine Advisers's largest Q2 2016 buy was S&P Global: 401,386 shares worth $43.1M.
  • RhumbLine Advisers added most to ExxonMobil in Q2 2016, an estimated $33.4M increase.
  • RhumbLine Advisers's biggest Q2 2016 reduction was Coca-Cola Europacific Partners, cutting an estimated $16.1M.
  • RhumbLine Advisers fully exited TIME WARNER CABLE INC NEW COM STK in Q2 2016, selling an estimated $86.8M.
  • RhumbLine Advisers's ten largest holdings make up 15% of its $33.7B portfolio in Q2 2016.
  • RhumbLine Advisers opened 144 new positions and closed 155 in Q2 2016.
  • RhumbLine Advisers's portfolio value rose 4.7% quarter-over-quarter to $33.7B.

Based on RhumbLine Advisers's 13F filing for Q2 2016, filed 11 Aug 2016.